Agenus Inc. (NASDAQ:AGEN) to Post Q2 2024 Earnings of ($0.02) Per Share, B. Riley Forecasts

Agenus Inc. (NASDAQ:AGENFree Report) – Research analysts at B. Riley raised their Q2 2024 earnings per share estimates for Agenus in a research report issued on Wednesday, May 8th. B. Riley analyst M. Mamtani now anticipates that the biotechnology company will post earnings of ($0.02) per share for the quarter, up from their previous estimate of ($4.92). B. Riley currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Agenus’ current full-year earnings is ($9.70) per share. B. Riley also issued estimates for Agenus’ Q3 2024 earnings at ($2.82) EPS, Q4 2024 earnings at $1.39 EPS, FY2024 earnings at ($4.66) EPS, FY2025 earnings at ($6.82) EPS, FY2026 earnings at ($4.13) EPS, FY2027 earnings at ($2.27) EPS and FY2028 earnings at $0.27 EPS.

A number of other equities analysts have also commented on AGEN. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Agenus in a research note on Tuesday, May 7th. StockNews.com assumed coverage on Agenus in a research note on Wednesday, April 17th. They issued a “hold” rating on the stock.

View Our Latest Research Report on AGEN

Agenus Price Performance

Agenus stock opened at $10.70 on Monday. The stock’s 50 day moving average is $10.51 and its 200 day moving average is $13.07. The firm has a market cap of $224.70 million, a P/E ratio of -0.83 and a beta of 1.25. Agenus has a one year low of $4.78 and a one year high of $42.60.

Agenus (NASDAQ:AGENGet Free Report) last posted its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($2.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($2.20). The company had revenue of $83.80 million during the quarter, compared to the consensus estimate of $54.21 million.

Institutional Investors Weigh In On Agenus

Institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC bought a new position in Agenus in the 3rd quarter valued at $36,000. PCG Wealth Advisors LLC lifted its position in shares of Agenus by 65.7% during the 4th quarter. PCG Wealth Advisors LLC now owns 47,550 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 18,850 shares during the last quarter. RPO LLC purchased a new position in shares of Agenus during the 4th quarter valued at $43,000. First Command Advisory Services Inc. purchased a new position in shares of Agenus during the 3rd quarter valued at $80,000. Finally, Ables Iannone Moore & Associates Inc. purchased a new position in shares of Agenus during the 4th quarter valued at $65,000. Institutional investors own 61.46% of the company’s stock.

Insider Activity

In other news, insider Garo H. Armen acquired 25,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was purchased at an average price of $13.00 per share, for a total transaction of $325,000.00. Following the completion of the acquisition, the insider now directly owns 31,298 shares in the company, valued at approximately $406,874. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 4.80% of the company’s stock.

About Agenus

(Get Free Report)

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Recommended Stories

Earnings History and Estimates for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.